

SCIENCE
IN FOOD
INGREDIENTS

Business Update Conference Call

4th Quarter Fiscal Year 2024

October 2, 2024



Disclaimer



The information presented herein includes forward-looking statements, projections, and estimates based on Moolec’s internal analysis, management estimates, and publicly disclosed information within the industry. These estimates and projections are subject to various risks and uncertainties that could cause actual results to differ materially from those anticipated. Moolec assumes no obligation to update any forward-looking statements or projections, whether as a result of new information, future events, or otherwise. The data presented is for informational purposes only and should not be relied upon as definitive or all-encompassing.

Forward-Looking Statements

This presentation contains “forward-looking statements.” Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this [press release/ presentation / publication] will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec’s business and other risks and uncertainties, including those included under the header “Risk Factors” in Moolec’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (“SEC”), as well as Moolec’s other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.

Industry and Market Data; Trademarks and Trade Names

In this presentation, Moolec relies on and refers to information and statistics regarding the market in which Moolec competes and other industry data. Moolec obtained this information and statistics from third-party sources, including reports by market research firms. Accordingly, none of Moolec nor its affiliates and advisors make any representations as to the accuracy or completeness of these data. Moolec has supplemented this information where necessary with information from Moolec’s own internal estimates, taking into account publicly available information about other industry participants and Moolec’s management’s best view as to information that is not publicly available. Moolec also owns or has rights to various trademarks, service marks and trade names that it uses in connection with the operation of its businesses. This presentation also contains trademarks, service marks and trade names of third parties, which are the property of their respective owners. The use or display of third parties’ trademarks and Moolec’s use thereof does not imply an affiliation with, or endorsement by the owners of such trademarks, copyrights, logos and other intellectual property. Solely for convenience, the trademarks, service marks and trade names referred to in this presentation may appear without the ®, TM or SM symbols, but such references are not intended to indicate, in any way, that Moolec will not assert, to the fullest extent under applicable law, its rights or the right of the applicable licensor to these trademarks, service marks and trade names. Moolec takes all necessary action to respect all intellectual property rights.

No Offer or Solicitation

This presentation is for informational purposes only and is neither an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy any securities or the solicitation of any vote in any jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.




Agenda

1
FY 2024 Annual Review
(Milestones)

2
Financial Overview

3
FY 2025: A Pivotal Year





SCIENCE
IN FOOD
INGREDIENTS

1. FY 2024 Annual Review (Milestones)





FY 2024 Annual Review (Milestones)

Piggy Sooy™
Level of Expression
stabilization in T3 seeds



Q1



Self-owned Molecular
Biology Labs
in the US




Q1

GLASO™
Trial production on partner
processor facility



Q3



Piggy Sooy™
USDA-APHIS
Approval (RSR)



Q3

Piggy Sooy™
FT and seed increase
in 3 different US locations



Q4



GLASO™
600 acres campaign
in Idaho, US



Q4





FY 2024 Annual Review (Milestones) | 1st half



Self-owned Molecular Biology Labs in the US

Leveraging on knowledge and networking of one of the most prestigious Universities for ag-tech

College Station, TX




Benefits

- Focused visio
- Costs reductio
- Clear chain of command (stewardship)
- Quick implementation of decision
- Higher control standard
- Improved quality of wor



Piggy SooyTM Level of Expression stabilization in T3 seeds

Second consecutive generation of high amounts of animal proteins in Moolec's genetically engineered soybean seeds





FY 2024 Annual Review (Milestones) | 2nd half



Piggy Sooy™ USDA-APHIS Approval (RSR)

First company to achieve regulatory clearance for producing animal meat proteins in plants



GLASO™ trial production on partner processor facility

Preliminary testings in third-party toll facility to optimize the process and upcoming production




GLASO™ 600 acres + Piggy Sooy™ FT and seed increase

US campaigns for genetically engineered plant-grown products in Idaho and Iowa, Missouri and Ohio

Why is this relevant for biotechnology?

Moolec is a flagship in Molecular Farming technology for 12+ companies currently participating in this space. USDA-APHIS RSR determines that Moolec's genetically engineered soybean is unlikely to pose an increased plant pest risk relative to non-engineered soybeans.






SCIENCE
IN FOOD
INGREDIENTS

2. Financial Overview




Financial Highlights for the Full FY2024


Revenue & Other Income¹




Cost of Sales¹



SG&A and R&D Expenses



Cash used in Operating Activities





3. FY 2025: A Pivotal Year



FY 2025: A Pivotal Year

Commercial Traction

- Volume/Revenue
- Sampling
- Licencing Models



Operational Focus

- Upstream & Downstream yields & quality assurance
- Seed inventory scale-up
- Cost efficiency & logistics
- Regulatory advancements



R&D and Product Development


- Pipeline grow
- Partners/Customers for new Product Developments



Team Consolidation

- Operation hub in the US
- Sales & Marketing
- Presence in shows to expand network and business





SCIENCE
IN FOOD
INGREDIENTS

Let's redefine
the way we
produce animal
proteins **for the
good of the planet.**




NASDAQ:MLEC

 hello@moolecscience.com | ir@moolecscience.com



Consolidated Statements of Operations

	For the three months ended June 30, 2024 (In thousands of U.S. dollars, unless otherwise noted)	For the three months ended June 30, 2023 (In thousands of U.S. dollars, unless otherwise noted)	Change %	For the fiscal year ended June 30, 2024 (In thousands of U.S. dollars, unless otherwise noted)	For the fiscal year ended June 30, 2023 (In thousands of U.S. dollars, unless otherwise noted)	Change %
Continuing operations						
Revenue	1,523.1	905.0	68%	5,625.1	905.0	522%
Cost of sales	(1,594.7)	(1,048.4)	52%	(5,152.5)	(1,048.4)	391%
Other income	99.9	-	N/A	495.5	-	N/A
Research and development expense	(420.9)	(370.6)	14%	(1,772.3)	(1,351.2)	31%
Marketing expense	(182.1)	(202.3)	(10%)	(643.1)	(256.4)	151%
Administrative expense	(2,362.3)	(3,322.3)	(29%)	(7,522.9)	(4,808.7)	56%
Other operating expense	(2.9)	(45.0)	(94%)	(72.7)	(94.2)	(23%)
Loss from operations	(2,939.9)	(4,083.6)	(28%)	(9,042.9)	(6,653.9)	36%
Financial cost	(609.9)	(160.0)	281%	(1,165.4)	(160.0)	628%
Other financial results	311.6	1,260.9	(75%)	1,869.0	1,030.5	81%
Transaction expenses	-	-	N/A	-	(3,535.0)	(100%)
Share-based payment cost of listing of shares	-	-	N/A	-	(42,705.1)	(100%)
Loss in investment in associates	(19.9)	-	N/A	(19.9)	-	N/A
Loss before income tax	(3,258.1)	(2,982.7)	9%	(8,359.2)	(52,023.5)	(84%)
Income tax	722.7	234.5	208%	1,047.0	234.5	346%
Loss of the period	(2,535.4)	(2,748.2)	(8%)	(7,312.2)	(51,789.0)	(86%)
Foreign exchange differences on translation of foreign operations	173.6	18.1	859%	107.6	18.1	494%
Total comprehensive loss for the period	(2,361.8)	(2,730.1)	(13%)	(7,204.6)	(51,770.9)	(86%)
Basic and diluted loss per share	(0.07)	(0.07)	0%	(0.19)	(1.50)	(87%)





Condensed Consolidated Statements of Financial Position

	As of June 30, 2024	As of June 30, 2023	Change %
	(In thousands of U.S. dollars, unless otherwise noted)		
Current assets	13,748.4	5,331.8	158%
Non-current assets	21,038.5	18,719.4	12%
Total assets	34,786.9	24,051.2	45%
Equity	6,815.7	10,106.0	(33%)
Current liabilities	8,150.4	12,599.1	(35%)
Non-current liabilities	19,820.8	1,346.1	1,372%
Total liabilities	27,971.2	13,945.2	101%
Total liabilities and equity	34,786.9	24,051.2	45%





Condensed Consolidated Statements of Cash Flows

	For the fiscal year ended June 30, 2024	For the fiscal year ended June 30, 2023	Change %
(In thousands of U.S, unless otherwise noted)			
Net cash (used) / generated in operating	(9,328.3)	(7,511.4)	24%
Net cash (used) / generated from investing activities	134.9	(2,336.8)	(106%)
Net cash (used) / generated from financing activities	11,711.4	11,281.7	4%
Net (decrease) / increase in cash and cash equivalents	2,518.0	1,433.5	76%
Cash and cash equivalents at beginning of the year	2,527.7	1,081.8	134%
Effect of exchange rate changes and inflation on cash equivalents	344.3	12.4	2,677%
Cash and cash equivalents at the end of the year	5,390.0	2,527.7	113%

